Angiogenesis Research to Improve Therapies for Vascular Leak Syndromes, Intra-Abdominal Adhesions, and Arterial Injuries
Abstract
The three goals of this project are: (i) to discover and develop novel drugs which could prevent or reverse the vascular leak syndrome; (ii) to develop angiogenesis inhibitors which would inhibit post-operative abdominal adhesions; and, (iii) to isolate endothelial progenitor cells from blood, capable of being expanded in vitro and applied to vascular grafts. Progress has been made in each category: we have made considerable progress in determining the efficacy of three anti-angiogenic agents in preventing vascular permeability in experimental model systems; we have developed a new blood cleansing platform that may have great value for treatment of infected patients with sepsis; we established that sunitinib prevents and reduces postoperative intra-abdominal adhesions in rabbits at a dose of 10 mg/kd/day; we determined that sunitinib reduces bowel anastomotic bursting pressure when used at the current dose and duration of treatment; we have shown that the human EPC/MPC system for building vascular networks is versatile in that it occurs in a variety of 3-dimensional environments, and that a transient influx of murine neutrophils 1-2 days after implantation of EPCs/MPCs/Matrigel is an important contributor to vasculogenesis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2009
- Accession Number
- ADA504045
Entities
People
- Donald E. Ingber